Sort   by:  
 Page size 
ProteomicsProtein response of lncRNA-DRC to HU treatment
protein response of lncRNA-DRC overexpression (mec1Δ sml1Δ-lncRNA-DRC-OE) to HU treatment
ORGANISM(S): Saccharomyces Cerevisiae 
2024-10-10 | PXD056715 |
ProteomicsThe antibacterial mechanism of sertindole against Staphylococcus aureus
Clinically isolated MRSA strain was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Sertindole was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added as L...
ORGANISM(S): Staphylococcus Aureus 
2022-07-14 | PXD035364 |
ProteomicsRepurposing Etalocib suppresses multidrug-resistant staphylococcus aureus
Staphylococcus aureus (S. aureus) is common gram-positive bacteria that prominently causes community acquired infection (CAI) and hospital acquired infection (HAI) makes it a versatile and dangerous, Antibiotic resistance and the long - term nature of new drug research and development have forced th...
ORGANISM(S): Staphylococcus Aureus 
2024-11-11 | PXD057734 |
ProteomicsGSK2018682 against Staphylococcus aureus proteome
Staphylococcus aureus (S, aureus) is common gram-positive bacteria that prominently causes community acquired infection (CAl) and hospital acquired infection (HAl) makes it a versatile and dangerous, Antibiotic resistance and the long - term nature of new drug research and development have forced th...
ORGANISM(S): Staphylococcus Aureus 
2025-08-01 | PXD066899 |
ProteomicsComparison of the significantly differentially expressed protein between K2044, K2044-8Xyl-60G, K2044-ΔXylA and K2044-ΔXylB treated with 8% xylose
The K. pneumoniae K2044, K2044-8Xyl-60G, K2044-ΔXylA and K2044-ΔXylB isolates were cultured overnight in MRS medium, then 1:200 diluted in MRS medium with 8% xylose to reach the exponential growth phase. The control group was K2044 treated with 8% xylose. The experiment was performed in triplicate.
ORGANISM(S): Klebsiella Pneumoniae 1191100241 
2024-11-04 | PXD057506 |
ProteomicsProteomic response of S. aureus to alpha-mangostin
S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. alpha-mangostin was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the contro...
ORGANISM(S): Staphylococcus Aureus 
2022-10-17 | PXD037518 |
Proteomicsproteomic response of S. aureus with entrectinib treatment
S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Entrectinib was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control gr...
ORGANISM(S): Staphylococcus Aureus 
2022-11-23 | PXD038342 |
ProteomicsAntibacterial and Anti-virulence Activity of the Repurposed Agent SX-682 Against Staphylococcus aureus
Proteomics of Staphylococcus aureus SA113 after treatment with SX - 682
ORGANISM(S): Staphylococcus Aureus Subsp. Aureus Nctc 8325 
2025-12-31 | PXD072538 |
ProteomicsMLS0315771 S. aureus YUSA145 proteomics
Quantitative label-free proteomic analysis investigated the global proteomic response of S. aureus YUSA145 treated with 1/2 × MIC MLS0315771 during the exponential growth phase. The results were obtained after performing principal component analysis (PCA) on the raw data and excluding two replicates...
ORGANISM(S): Staphylococcus Aureus 
2026-01-24 | PXD073535 |
ProteomicsAzeliragon for the treatment of Staphylococcus aureus proteome
Azeliragon for the treatment of Staphylococcus aureus proteome
ORGANISM(S): Staphylococcus Aureus 
2025-10-27 | PXD069935 |
Sort   by:  
 Page size